Invention Grant
- Patent Title: Artificial signal peptide
-
Application No.: US15239127Application Date: 2016-08-17
-
Publication No.: US09908928B2Publication Date: 2018-03-06
- Inventor: Oliver Hill , Christian Gieffers , Meinolf Thiemann
- Applicant: APOGENIX AG
- Applicant Address: DE Heidelberg
- Assignee: Apogenix AG
- Current Assignee: Apogenix AG
- Current Assignee Address: DE Heidelberg
- Agency: Perkins Coie LLP
- Agent Viola T. Kung
- Priority: EP12176978 20120718; EP12176980 20120718
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K7/08 ; C07K16/00 ; C07K14/525 ; C07K16/18 ; A61K38/17 ; A61K39/395
Abstract:
The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.
Public/Granted literature
- US20160362471A1 SHORTENED CD95-FC VARIANTS Public/Granted day:2016-12-15
Information query
